Clinical Trial Update: Neoadjuvant Ivonescimab（AK112） Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 neoadjuvant trial evaluating Ivonescimab (AK112) plus chemotherapy in patients with resectable esophageal squamous cell carcinoma; the study is not yet …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy | Phase 2 | Status: NOT_YET_RECRUITING